FAM
TVTX icon

Fred Alger Management’s Travere Therapeutics TVTX Stock Holding History

Fred Alger Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56M Sell
86,236
-8,596
-9% -$257K 0.01% 292
2025
Q4 		$3.62M Sell
94,832
-27,197
-22% -$884K 0.01% 272
2025
Q3 		$2.92M Buy
+122,029
New +$2.29M 0.01% 294

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fred Alger Management's TVTX Position: Q1 2026 in Review

Fred Alger Management reduced its Travere Therapeutics (TVTX) stake by 9.1% in Q1 2026, selling an estimated $257K and leaving 86,236 shares worth $2.56M. The position accounts for 0.01% of the portfolio, ranked #292.

Fred Alger Management first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.62M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Fred Alger Management held 86,236 shares of Travere Therapeutics worth $2.56M as of Q1 2026.
  • Fred Alger Management sold 8,596 Travere Therapeutics shares in Q1 2026, an estimated $257K.
  • Travere Therapeutics made up 0.01% of Fred Alger Management's portfolio in Q1 2026, its #292 holding.
  • Fred Alger Management first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fred Alger Management's Travere Therapeutics position peaked at $3.62M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.